Genmab AS Quote - GE9

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

204.80

Bid

202.50

Offer

204.40

Volume

222

202.00 Day's Range 204.80

188.60 52 Week Range 291.40

Market Cap

13.454B

Previous Close

201.40

Open

202.50

Last Trade

204.8

Last Trade Time

05:33:00

Financial Volume

VWAP

Average Volume (3m)

375

Shares Outstanding

65,691,573

Dividend Yield

PE Ratio

3.23

Earnings Per Share (EPS)

66.25

Revenue

16.47B

Net Profit

4.35B

Sector

Biological Pds,ex Diagnstics

Industry

Biogenetic (human)

Website

www.genmab.com

Headquarters

Copenhagen, Dnk

Founded

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GE9. The last closing price for Genmab AS was 201.40 €. Over the last year, Genmab AS shares have traded in a share price range of 188.60 € to 291.40 €.

Genmab AS currently has 65,691,573 shares in issue. The market capitalisation of Genmab AS is 13.23 € billion. Genmab AS has a price to earnings ratio (PE ratio) of 3.23.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024 Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from...

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; January 03, 2025Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel...

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 –...

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell...

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Media...

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by...

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab...

Genmab to Present at Citi’s Global Healthcare Conference

Genmab to Present at Citi’s Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	3.6	1.78926441352	201.2	211.4	195.8	599	203.52132844	DE
4	4.4	2.19560878244	200.4	217.8	193.25	376	204.76075176	DE
12	-1.9	-0.919206579584	206.7	220.8	188.6	375	203.74848316	DE
26	-50.4	-19.7492163009	255.2	264.7	188.6	299	215.52932353	DE
52	-58.4	-22.188449848	263.2	291.39999	188.6	243	231.96933201	DE
156	-90	-30.5291723202	294.8	362.9	188.6	188	242.51529249	DE
260	-168.8	-45.182012848	373.6	374.3	188.6	172	242.85535051	DE

GE9 - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?

The current share price of Genmab AS is 204.80 €

How many Genmab AS shares are in issue?

Genmab AS has 65,691,573 shares in issue

What is the market cap of Genmab AS?

The market capitalisation of Genmab AS is EUR 13.23B

What is the 1 year trading range for Genmab AS share price?

Genmab AS has traded in the range of 188.60 € to 291.40 € during the past year

What is the PE ratio of Genmab AS?

The price to earnings ratio of Genmab AS is 3.23

What is the cash to sales ratio of Genmab AS?

The cash to sales ratio of Genmab AS is 0.85

What is the reporting currency for Genmab AS?

Genmab AS reports financial results in DKK

What is the latest annual turnover for Genmab AS?

The latest annual turnover of Genmab AS is DKK 16.47B

What is the latest annual profit for Genmab AS?

The latest annual profit of Genmab AS is DKK 4.35B

What is the registered address of Genmab AS?

The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260

What is the Genmab AS website address?

The website address for Genmab AS is www.genmab.com

Which industry sector does Genmab AS operate in?

Genmab AS operates in the BIOGENETIC (HUMAN) sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
H7KPeak Minerals Limited	0.009 € (38.46%)	5k
AAHAhlers AG	0.011 € (37.50%)	3k
8XJAfrican Gold Limited	0.048 € (35.21%)	51.48k
D4GDataMetrex AI Ltd	0.0074 € (32.14%)	23k
N7ONLightbridge Corp	9.10 € (31.88%)	13.2k
POTAPortofino Resources Inc	0.0026 € (-50.00%)	500
LL3PanGenomic Health Inc	0.127 € (-46.84%)	126
VAR1Varta AG	0.8495 € (-43.74%)	1.65M
SL5Recharge Resources Ltd	0.0208 € (-41.24%)	500
M000Vertical Aerospace Ltd	5.35 € (-39.89%)	11.21k
PF8European Lithium Limited	0.0362 € (-10.40%)	11.25M
W1HOnco Innovations Limited	1.406 € (16.20%)	2.66M
D7GNel ASA	0.1914 € (0.16%)	2.61M
RQ0DWave Quantum Inc	5.726 € (-4.53%)	1.97M
432Arbor Metals Corp	0.3665 € (16.72%)	1.7M